Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
| Autor: | Maarten van der Vliet, Barnaby Hunt, Divina Glah |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Insulin degludec
medicine.medical_specialty HbA1c GLP-1 analogs Cost effectiveness Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes Insulin aspart 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Internal Medicine medicine Original Research Glycemic business.industry Insulin glargine Liraglutide 030503 health policy & services medicine.disease Hypoglycemia Surgery Insulin analogs 0305 other medical science business medicine.drug |
| Zdroj: | Diabetes Therapy |
| ISSN: | 1869-6961 1869-6953 |
| DOI: | 10.1007/s13300-017-0266-3 |
| Popis: | Introduction Insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (T2DM) who are uncontrolled on basal insulin and require treatment intensification. The objective of this analysis was to evaluate the long-term cost-effectiveness of IDegLira versus basal-bolus therapy (insulin glargine U100 + 3× daily insulin aspart) for patients with T2DM uncontrolled on basal insulin [HbA1c >53 mmol/mol (>7%)] in the Netherlands. Methods Cost-effectiveness analysis was performed using the validated IMS CORE Diabetes Model from a healthcare payer perspective. Outcomes were modeled over patient lifetimes in a cohort with baseline characteristics from the DUAL™ II trial. Treatment effect data were sourced from a statistical indirect comparison (pooled analysis) of IDegLira with basal-bolus therapy. Results Treatment with IDegLira resulted in mean increases in quality-adjusted life expectancy of 0.43 quality-adjusted life years versus basal-bolus therapy. Improved clinical outcomes resulted from fewer diabetes-related complications and a delayed time to their onset. IDegLira was associated with lower costs of EUR 4679 versus basal-bolus therapy, a result of lower pharmacy costs and avoided diabetes-related complications. Thus, IDegLira was dominant, i.e., both more effective and less costly than basal-bolus therapy. Conclusions IDegLira is an effective treatment option to improve glycemic control without incurring an increased risk of hypoglycemia or weight gain. This analysis suggests that IDegLira is cost-effective versus basal-bolus therapy in patients with T2DM who are uncontrolled on basal insulin in the Netherlands. Funding Novo Nordisk. Electronic supplementary material The online version of this article (doi:10.1007/s13300-017-0266-3) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|